BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20329570)

  • 21. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
    Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department.
    Miner JR; Moore J; Gray RO; Skinner L; Biros MH
    Acad Emerg Med; 2008 Dec; 15(12):1234-40. PubMed ID: 18945240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules.
    Nicholson B; Ross E; Weil A; Sasaki J; Sacks G
    Curr Med Res Opin; 2006 Mar; 22(3):539-50. PubMed ID: 16574037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
    Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy switching in patients receiving long-acting opioids.
    Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
    Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.
    Silvestri B; Bandieri E; Del Prete S; Ianniello GP; Micheletto G; Dambrosio M; Sabbatini G; Endrizzi L; Marra A; Aitini E; Calorio A; Garetto F; Nastasi G; Piantedosi F; Sidoti V; Spanu P
    Clin Drug Investig; 2008; 28(7):399-407. PubMed ID: 18544000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer.
    Suzuki T; Morishita M; Ito E; Matsuura M; Tanaka R; Saito T
    Am J Ther; 2008; 15(1):31-5. PubMed ID: 18223351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.
    Schutter U; Grunert S; Meyer C; Schmidt T; Nolte T
    Curr Med Res Opin; 2010 Jun; 26(6):1377-87. PubMed ID: 20380506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of oxycodone/acetaminophen and codeine/acetaminophen vs. conventional therapy in elderly women with persistent, moderate to severe osteoarthritis-related pain.
    Corsinovi L; Martinelli E; Fonte G; Astengo M; Sona A; Gatti A; Massaia M; Bo M; Zanocchi M; Michelis G; Isaia G; Molaschi M
    Arch Gerontol Geriatr; 2009; 49(3):378-82. PubMed ID: 19150139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
    Hagen NA; Babul N
    Cancer; 1997 Apr; 79(7):1428-37. PubMed ID: 9083166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of sustained release morphine hydrochloride tablets in management of cancer pain: a survey of 567 patients].
    Yu SY; Qiu H; Ma ZS; Chen J; Zhang Y; Chen LZ; Wang DL; Ma ZY
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(6):450-5. PubMed ID: 15061959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.
    Daniels S; Casson E; Stegmann JU; Oh C; Okamoto A; Rauschkolb C; Upmalis D
    Curr Med Res Opin; 2009 Jun; 25(6):1551-61. PubMed ID: 19445652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Controlled release oxycodone--a new option in the treatment of severe and very severe pain. Review of studies on neuropathic, physical activity-related and postoperative pain].
    Stiehl M
    MMW Fortschr Med; 2004 Aug; 146 Suppl 2():61-9. PubMed ID: 16739361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol.
    Samolsky Dekel BG; Tomasi M; Vasarri A; Gori A; Adversi M; Castagnoli A; Di Nino G; Melotti RM
    J Opioid Manag; 2014; 10(1):29-38. PubMed ID: 24604567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of oxycodone, ibuprofen, or the combination in the initial management of orthopedic injury-related pain in children.
    Koller DM; Myers AB; Lorenz D; Godambe SA
    Pediatr Emerg Care; 2007 Sep; 23(9):627-33. PubMed ID: 17876251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.